{Reference Type}: Journal Article
{Title}: Polygenic subtype identified in ACCORD trial displays a favorable type 2 diabetes phenotype in the UKBiobank population.
{Author}: Hershberger C;Mariam A;Pantalone KM;Buse JB;Motsinger-Reif AA;Rotroff DM;
{Journal}: Hum Genomics
{Volume}: 18
{Issue}: 1
{Year}: 2024 Jun 22
{Factor}: 6.481
{DOI}: 10.1186/s40246-024-00639-z
{Abstract}: <B>BACKGROUND: </B>We previously identified a genetic subtype (C4) of type 2 diabetes (T2D), benefitting from intensive glycemia treatment in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Here, we characterized the population of patients that met the C4 criteria in the UKBiobank cohort.<BR><B>METHODS: </B>Using our polygenic score (PS), we identified C4 individuals in the UKBiobank and tested C4 status with risk of developing T2D, cardiovascular disease (CVD) outcomes, and differences in T2D medications.<BR><B>RESULTS: </B>C4 individuals were less likely to develop T2D, were slightly older at T2D diagnosis, had lower HbA1c values, and were less likely to be prescribed T2D medications (P < .05). Genetic variants in MAS1 and IGF2R, major components of the C4 PS, were associated with fewer overall T2D prescriptions.<BR><B>CONCLUSIONS: </B>We have confirmed C4 individuals are a lower risk subpopulation of patients with T2D.